
News|Podcasts|March 10, 2025
Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast
Author(s)Linda Stein Gold, MD, Sydney Jennings
“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.
Advertisement
Linda Stein Gold, MD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial. Interview recorded at the 2025 American Academy of Dermatology conference in Orlando, Florida.
Topics discussed include:
- Key insights from the new analysis of the ADORING-3 clinical trial on the use of tapinarof cream, 1% in patients with atopic dermatitis.
- Long-term safety and efficacy of tapinarof cream 1%.
- How tapinarof cream 1% differs from existing treatment options.
- Impacts on clinical practice.
For more 2025 AAD Meeting coverage, please click here.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Avoiding Common Ordering Errors in UACR Testing, With Holly Kramer, MD
2
Nationwide Survey Finds Widespread Concern About Topical Steroid Use, Emphasizes Need for Long-Term Management Strategies in Chronic Inflammatory Skin Disease
3
Healthiest States in America: A 2025 Ranking
4
Sebela Submits NDA for Tegoprazan for GERD, Seeking Approval for NERD and Erosive Esophagitis
5























































































































































































































































































































